[go: up one dir, main page]

MX2014015345A - Inhibidores piranopiridona de tanquirasa. - Google Patents

Inhibidores piranopiridona de tanquirasa.

Info

Publication number
MX2014015345A
MX2014015345A MX2014015345A MX2014015345A MX2014015345A MX 2014015345 A MX2014015345 A MX 2014015345A MX 2014015345 A MX2014015345 A MX 2014015345A MX 2014015345 A MX2014015345 A MX 2014015345A MX 2014015345 A MX2014015345 A MX 2014015345A
Authority
MX
Mexico
Prior art keywords
pyranopyridone
tankyrase
inhibitors
compounds
activity
Prior art date
Application number
MX2014015345A
Other languages
English (en)
Inventor
Johannes Cornelius Hermann
Javier De Vicente Fidalgo
Lin Yi
Mark Zak
David Robert Bolin
Parcharee Tivitmahaisoon
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014015345A publication Critical patent/MX2014015345A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proporcionan compuestos de fórmula: (ver Fórmulas) o una sal farmacéuticamente aceptable de los mismos, en los que X, M, Y, R1 y R2 son tal como se define en la presente memoria. Los compuestos presentan actividad como agentes anticáncer.
MX2014015345A 2012-06-20 2013-06-18 Inhibidores piranopiridona de tanquirasa. MX2014015345A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661915P 2012-06-20 2012-06-20
PCT/EP2013/062563 WO2013189904A1 (en) 2012-06-20 2013-06-18 Pyranopyridone inhibitors of tankyrase

Publications (1)

Publication Number Publication Date
MX2014015345A true MX2014015345A (es) 2015-03-05

Family

ID=48628700

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015345A MX2014015345A (es) 2012-06-20 2013-06-18 Inhibidores piranopiridona de tanquirasa.

Country Status (12)

Country Link
US (1) US20140121231A1 (es)
EP (1) EP2864335A1 (es)
JP (1) JP2015520204A (es)
KR (1) KR20150009599A (es)
CN (1) CN104284898A (es)
AR (1) AR091520A1 (es)
BR (1) BR112014031785A2 (es)
CA (1) CA2869239A1 (es)
HK (1) HK1201066A1 (es)
MX (1) MX2014015345A (es)
RU (1) RU2014152792A (es)
WO (1) WO2013189904A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
WO2013189905A1 (en) * 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag Pyrrolopyrazone inhibitors of tankyrase
WO2014087165A1 (en) * 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors
AU2014320149A1 (en) 2013-09-11 2016-04-07 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
CN106536478A (zh) * 2014-05-22 2017-03-22 悉尼大学 ω‑3类似物
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN117120447A (zh) * 2021-03-18 2023-11-24 薛定谔公司 环状化合物和其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247641B2 (en) * 2001-08-07 2007-07-24 Mgi Gp, Inc. Compounds, derivatives, compositions, preparation and uses
MXPA06009701A (es) * 2004-02-26 2007-03-26 Inotek Pharmaceuticals Corp Derivados de isoquinolina y metodos de uso de los mismos.
WO2006039545A2 (en) * 2004-09-30 2006-04-13 Maxim Pharmaceuticals, Inc. Use of parp-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
US7576080B2 (en) 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
WO2006106052A1 (en) 2005-04-05 2006-10-12 F. Hoffmann-La Roche Ag Pyrazoles
US20080242861A1 (en) 2007-04-02 2008-10-02 Chi-Feng Yen Synthesis of amino-protected cyclohexane-1,4-diyldimethanamine and its derivatives
WO2010011375A2 (en) 2008-04-21 2010-01-28 Merck & Co., Inc. Inhibitors of janus kinases

Also Published As

Publication number Publication date
CA2869239A1 (en) 2013-12-27
RU2014152792A (ru) 2016-08-10
HK1201066A1 (en) 2015-08-21
EP2864335A1 (en) 2015-04-29
AR091520A1 (es) 2015-02-11
KR20150009599A (ko) 2015-01-26
JP2015520204A (ja) 2015-07-16
BR112014031785A2 (pt) 2017-06-27
WO2013189904A1 (en) 2013-12-27
US20140121231A1 (en) 2014-05-01
CN104284898A (zh) 2015-01-14

Similar Documents

Publication Publication Date Title
MX2014014832A (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa.
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
MX361499B (es) Baricitinib deuterado.
PH12014500883A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
MY165238A (en) Substituted pyrrolidine-2-carboxamides
IN2015DN01035A (es)
PH12014501653A1 (en) Metalloenzyme inhibitor compounds
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
IN2015DN00598A (es)
IN2014DN10670A (es)
NZ723772A (en) Neprilysin inhibitors
MX353024B (es) Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2014015345A (es) Inhibidores piranopiridona de tanquirasa.
GB201209587D0 (en) Therapeutic compounds
WO2014062838A3 (en) Pkm2 modulators and methods for their use
IN2014DN07996A (es)
MY168752A (en) Carbamate/urea derivatives
PH12015500399A1 (en) Azaindolines
IN2014DN10669A (es)
IN2014DN07410A (es)
PH12015501056A1 (en) 2-pyridone compound
PH12015500282A1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
UA65243U (ru) Применение радиоактивного цисплатина как вещества с усиленным противоопухолевым действием